巴斯德研究所临床前研究
伊维菌素是一种针对 SARS-CoV-2 的强大免疫调节药物
位于法国的著名全球研究机构
在 EMBO Molecular Medicine 上发表了一项临床前研究，表明
伊维菌素与减轻 COVID-19 症状有关。
然而，即使在数十项研究在现实世界中展示了这样的结果之后，
世界卫生组织 (WHO)
尚未为低收入和中等收入国家 (LMIC) 抓住该药物的机会。
巴斯德研究所
让-皮埃尔·尚努
表明该药物作用于烟碱受体，这无疑将引发有关该主题的有趣辩论。
在一项涉及仓鼠的综合临床前研究中，研究团队
得出的结论是，伊维菌素是一种强大的免疫调节药物，这意味着它可以帮助世界对抗 COVID-19 大流行。
The study results reveal that the anti-parasitic drug ivermectin
prevents clinical deterioration, reduces olfactory deficit, and limits the inflammation of the upper and lower respiratory tracts in the study animals.
The investigators recommend consideration of the drug as a means to combat COVID-19.
The authors summarized that
the pandemic also necessitates a “search for immunomodulatory drugs that could improve disease outcome.”
In a preclinical hamster study,
the scientists at the Pasteur Instituteshowcased that the anti-parasitic drug ivermectin
prevents clinical deterioration,
reduces olfactory deficit,and limits the inflammation of the upper and lower respiratory tracts in SARS-CoV-2-infected hamsters.
The preclinical investigators in France
reported that the drug didn’t affect viral load in the infected animals’ airways.Moreover, after conducting transcriptomic analyses of infected lungs,
scientists there report that
ivermectin dampens type 1 interferon responses while modulating a number of additional inflammatory pathways.
Noteworthy, they reported that
ivermectin “dramatically reduces the Il-6/Il-10 ratio in lung tissue and promotes macrophage M2 polarization, which might account for the more favorable clinical presentation of IVM-treated animals.”